Cargando…
Mutant and non-mutant neoantigen-based cancer vaccines: recent advances and future promises
Major advances in cancer treatment have emerged with the introduction of immunotherapies using blocking antibodies that target T-cell inhibitory receptors, such as programmed death-1 (PD-1) and cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4), known as immune checkpoints. However, most cancer pa...
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Open Exploration
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9834040/ https://www.ncbi.nlm.nih.gov/pubmed/36654823 http://dx.doi.org/10.37349/etat.2022.00111 |